Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib with Albumin Paclitaxel and Trastuzumab in HER2+ Early/Locally Advanced Breast Cancer
NCT04152057Phase 2Unknown
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2019
- Primary completion
- Apr 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by West China Hospital of Sichuan University. Primary endpoint: pathologic Complete Response at 24 weeks. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04152057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152057.